Patients indicated a deficiency of the drug for the treatment of autoimmune diseases

Russian medical organizations have stopped issuing drugs with the active ingredient infliximab, patients with autoimmune diseases, including Ankylosing spondylitis and Crohn's disease, told Izvestia.

Window of denial: three regions do not dispense medicines for pituitary abnormalities

Interruption of therapy leads to heart failure and diabetes in patients, experts said

They noted that difficulties with the availability of such drugs have been observed since the fall of 2024.

According to the analytical company RNC Pharma, 52 thousand packages of drugs with infliximab were launched on the market in 2024, which is 46% less than in 2023.

"In 2023, 96 thousand packages were delivered, and in 2022 — about 70 thousand packages," they added.

The RNC also noted that last year the main suppliers of medicines with infliximab were the Russian companies Pharmapark and Biocad. And the last shipments of the drug produced by the American MSD were in 2023.

According to another analytical company, DSM Group, the state segment received 59.36 thousand packages of drugs with infliximab in 2024, and 1.25 thousand packages in January 2025. Last year, only 190 packages of the drug were sold through pharmacies.

Patients noted that it is really difficult to buy drugs with infliximab in pharmacies now. Although earlier, according to them, despite the lack of medicine in hospitals, it was possible to buy it there.

Izvestia analyzed data from pharmacy aggregators and found that infliximab drugs are currently unavailable in pharmacies in at least 69 regions.

Biocade, the only manufacturer of drugs with infliximab, which responded to a request from the editorial board, said that due to sanctions restrictions, they had revised "production models for certain types of raw materials necessary for the release of infliximab, which led to forced changes and a shift in the production schedule of the drug."

They also added that they could not yet give an accurate forecast on the availability of the drug.

Read more in the exclusive Izvestia article:

Mother of treatment: Russia lacks a drug for autoimmune diseases